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http://dxObjective: The study objective was to report the midterm outcomes of MitraClip implantation in inoperable or
high-risk surgical candidates with degenerative mitral regurgitation.
Methods: From October 2008, data of all high-risk or elderly patients with severe degenerative mitral
regurgitation who underwent MitraClip implantation were prospectively collected.
Results: Forty-eight high-risk consecutive patients with severe degenerative mitral regurgitation underwent
MitraClip implantation (mean age, 78.5  10.8 years; 56.6% of the patients were aged 80 years). Mean
Society of Thoracic Surgeons score was 12%  10%, and 71% were in New York Heart Association class
III or IV. Mean left ventricular ejection fraction was 57%  11%. The device was successfully implanted in
47 of 48 patients (98%). In-hospital mortality was 2%. The median intensive care unit stay was 22 hours;
patients were discharged from the hospital in an average of 4.5  2.4 days. Predischarge echocardiography
showed a mitral regurgitation reduction to grade 2þ or less in 43 of 47 patients (91.5%). Actuarial survival
was 89%  5.2% and 70.2%  9% at 1 and 2 years, respectively (82%  9% in patients aged<80 years
and 95% 4.4% in patients aged80 years at 1 year; P¼ .9). Freedom frommitral regurgitation 3þ or greater
was 80%  7% at 1 year and 76.6%  7% at 2 years. At 1 year, 93% of survivors were in New York Heart
Association class I or II (100% of patients aged<80 years and 88% of patients aged 80 years; P ¼ .4).
Significant quality of life improvements were documented. A significant improvement in 6-minute walk test
performance was observed.
Conclusions:MitraClip therapy is a valuable alternative to surgery in high-risk and elderly patients with degen-
erative mitral regurgitation. Clinical benefits also are obtained in octogenarians. (J Thorac Cardiovasc Surg
2014;148:2743-50)See related commentary on pages 2750-1.
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C
DSurgical repair represents the optimal treatment for severe
degenerative mitral regurgitation (DMR) because of its
well-documented advantages over valve replacement in
terms of perioperative mortality, preservation of postopera-
tive left ventricular function, and long-term survival.1,2
Indeed, if performed before the onset of limiting
symptoms or the development of left ventricular
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The Journal of Thoracic and Carnormal life expectancy and quality of life.3 Currently,
more than 90% of degenerative lesions can be repaired suc-
cessfully in high-volume centers, with low morbidity and
fast recovery.4-6 In view of these results, elective MV
repair may be indicated even in asymptomatic patients
with severe DMR.7
However, in real-world clinical practice, a large number
of patients with severe mitral regurgitation (MR) are denied
surgery: The Euro Heart Survey conducted by the European
Society of Cardiology showed that up to 50% of the pa-
tients with severe MR currently are denied surgical treat-
ment because they are thought to be at too high risk for
surgery because of advanced age or comorbidities.8 More-
over, the prevalence of DMR increases in elderly persons,9
and advanced age is one of the main risk factors of mortality
andmajor morbidity after cardiac surgery.10 Therefore, over
the past years, new transcatheter techniques have been
developed to treat MR with less-invasive approaches.
Although less effective in reducing MR compared with sur-
gical repair,11,12 MitraClip therapy (Abbott Vascular Inc,
Menlo Park, Calif) has been shown to improve functional
and clinical outcome in inoperable or high-risk pa-
tients.13-18 Few data are available today on the midterm
clinical outcomes of high-risk patients with DMR after
MitraClip implantation.diovascular Surgery c Volume 148, Number 6 2743
Abbreviations and Acronyms
ACCESS-EU ¼ ACCESS-EUROPE
DMR ¼ degenerative mitral regurgitation
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
EVEREST ¼ Efficacy of Vasopressin
Antagonism in Heart Failure
Outcome Study with Tolvaptan
IQR ¼ interquartile range
MLHFQ ¼ Minnesota Living with Heart
Failure Questionnaire
MR ¼ mitral regurgitation
MV ¼ mitral valve
NYHA ¼ New York Heart Association
6MWT ¼ 6-minute walk test
SF-36 ¼ 36-Item Short-Form Health Survey
STS ¼ Society of Thoracic Surgeons
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C
DThe aim of this study is to report the midterm clinical and
echocardiographic results of MitraClip therapy to treat
symptomatic high-risk or elderly patients with severe
DMR in a single high-volume center experience to validate
the use of MitraClip treatment in this specific setting.METHODS
We retrospectively analyzed the clinical and echocardiographic data of
a cohort of consecutive patients who underwent MitraClip therapy between
October 2008 and July 2013 for severe or moderately severe symptomatic
DMR. All patients underwent preoperative coronary angiography and
transesophageal Doppler echocardiography. Clinical, Doppler echocardio-
graphic, operative, and outcome data were prospectively collected in a
dedicated database. The study protocol was performed in accordance
with the institutional ethics committee, and all patients gave written
informed consent for the procedures and data collection.
Description of the Procedure
The procedure was performed under general anesthesia in a hybrid
operating room, under transesophageal Doppler echocardiography and
fluoroscopic guidance. Transseptal puncture was performed using a Brock-
enbrough needle (Medtronic Inc, Minneapolis, Minn) through peripheral
venous access at the right groin. Live real-time 3-dimensional echocardiog-
raphy was used to improve the conduct of the implantation. A steerable
guide catheter was advanced in the left atrium through the transseptal punc-
ture. The delivery system was inserted, and the MitraClip device was
implanted in correspondence with the origin of the regurgitation jet,
perpendicularly to the coaptation line. If the effect of the implant was satis-
factory, the clip was deployed. When necessary, more than 1 clip was
implanted. The comprehensive description of the procedure has been
reported by Maisano and colleagues.19
Patient Selection
Patients were selected if theymet basic criteria for intervention from the
European Society of Cardiology Task Force recommendation on the man-
agement of valvular heart disease.7 Indication for MitraClip therapy was
given according to local institutional practice in consideration of current
CE mark–approved labeling. Eligible patients included those with2744 The Journal of Thoracic and Cardiovascular Sursymptomatic moderate-to-severe (3þ) or severe (4þ) MR. Transthoracic
and transesophageal echocardiograms studies were evaluated at baseline
to assess patient eligibility.
All patients underwent a multimodality decision-making process by a
dedicated multidisciplinary Heart Team, including evaluation of surgical
risk by logistic European System for Cardiac Operative Risk Evaluation
(euroSCORE) (http://www.euroscore.org/) and Society of Thoracic Sur-
geons (STS) score (http://riskcalc.sts.org/STSWebRiskCalc273/), as well
as adjunctive risk evaluation, such as the presence of advanced liver
cirrhosis and severe neurologic impairment. Frailty and biological status
were evaluated by the institutional Heart Team after collegial discussion,
according to the so-called eyeball test. Quality of life of all the patients
was evaluated by the Minnesota Living with Heart Failure Questionnaire
(MLHFQ) and the 36-Item Short-Form Health Survey (SF-36); the
6-minute walk test (6MWT) was used to evaluate functional capacity.
Follow-up
All patients were followed up after discharge in a dedicated outpatient
clinic with physical examination, electrocardiogram, transthoracic echo-
cardiogram, and arrhythmology consultation whenever indicated.
Follow-up visits were performed at 1 month, 6 months, and then yearly.
Statistical Analysis
Statistical analysis was conducted using JMP 11.0 software (SAS Insti-
tute Inc, Cary, NC). Continuous variables are presented as mean standard
deviation or as median (interquartile range [IQR], Q1-Q3), and categoric
variables are expressed as percentages. Univariable comparisons were per-
formed with Student unpaired or paired t test for continuous normally
distributed data, which were tested by the Shapiro–Wilk normality test.
The Mann–Whitney rank-sum test was used for comparisons of nonpara-
metric continuous data, and the chi-square test was used for categoric
data. Survival and freedom from 3þ or greater MR were presented using
the Kaplan–Meier method; comparisons were performed with the log-
rank test. All reported P values are 2-sided.RESULTS
Patient Characteristics
The study population consisted of 48 high-risk consecu-
tive patients with severe or moderate to severe DMR who
underwent MitraClip implantation between October 2008
and July 2013 in San Raffaele University Hospital, Milan.
During the same period, 2370 patients underwent surgical
mitral repair (with or without associated procedure), and
116 patients underwent MitraClip implantation for func-
tional MR.
The mean age of the study population was 78.5  10.8
years; 56.6% of the patients were aged 80 years or more.
The mean logistic euroSCORE at baseline was 15.7 11.2;
the mean STS score was 12%  10% (range, 2%-36%;
IQR, 4-18); 40% and 45.5% of patients had a baseline
logistic euroSCORE 20% or greater and STS score 10%
or greater, respectively. Patients presented multiple comor-
bidities. The baseline characteristics of all the patients are
summarized in Table 1 (including data from ACCESS-
EUROPE (ACCESS-EU) phase I DMR cohort for com-
parison).13 Stratification into patients aged less than 80
years and patients aged 80 years or more revealed impor-
tant demographic differences (mean logistic euroSCOREgery c December 2014
TABLE 1. Baseline demographics and comorbidities
Characteristic Overall (n ¼ 48) Age<80 y (n ¼ 21) Age 80 y (n ¼ 27) P value
ACCESS-EU DMR
(n ¼ 117)
Age (y) 78.5  10.8 70.2  11 84.8  3 <.0001 75.6  12.1
Female (n,%) 22 (46) 9 (42) 13 (48) .7 59 (50.4)
Logistic euroSCORE (%) 15.7  12.2 12.1  8.5 18.5  12 .04 15.5  13.3
STS-PROM (%) 12  10 8.3  6 15.1  11 .02 na
Previous cardiac surgery (n,%) 10 (21) 6 (28) 4 (14) .2 28 (23.9)
Previous percutaneous intervention (n,%) 7 (14.5) 3 (14) 4 (14) .9 32 (27.6)
CAD (n,%) 19 (39.5) 9 (42) 10 (37) .7 48 (41)
AF (n,%) 25 (52) 7 (33) 18 (66) .02 67 (58.8)
Baseline serum creatinine (mg/dL) 1.1  0.4 0.9  0.2 1.3  0.3 .006 na
COPD (%) 14 (29) 6 (28) 8 (29) .3 17 (14.7)
Cerebrovascular disease (n,%) 5 (10.5) 1 (4) 4 (14) .2 12 (10.3)
Extracardiac arteriopathy (n,%) 6 (12.5) 2 (9) 4 (14) .6 na
Diabetes (n,%) 4 (8.3) 3 (6) 1 (4) .4 17 (14.5)
NYHA class III-IV (n,%) 34 (70.8) 14 (66) 20 (74) .5 113 (96.4)
Previous ICD-CRT (n,%) 1 (2) 0 1 (3.7) .3 2 (1.7)
Bold indicatesP<.05.ACCESS-EU, ACCESS-EUROPE;AF, atrial fibrillation;CAD, coronary artery disease;COPD, chronic obstructive pulmonary disease;DMR, degenerative
mitral regurgitation; euroSCORE, European System for Cardiac Operative Risk Evaluation; ICD-CRT, Implantable Cardioverter Defibrillator-Cardiac Resynchronization
Therapy; na, not available; NYHA, New York Heart Association; STS-PROM, Society of Thoracic Surgeons Predicted Risk of Mortality.
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D12.1%  8.5% and 18.5%  12%, respectively, P ¼ .04).
The majority of the patients had severe symptoms of heart
failure at baseline, with 60.5% in New York Heart Associa-
tion (NYHA) functional class III and 10.5% in class IV.
Quality of life questionnaire revealed an important impair-
ment in perceived quality of life in all patients (MLHFQwas
35.4  12; SF-36 physical domain was 38.6  7.9; SF-36
mental domain was 42.5  8.7). A tendency toward worst
perceived quality of life was observed in patients aged 80
years or more (MLHFQ 33  14 vs 36  8; P ¼ .3; SF-36
physical domain 40.6 6 vs 42.4 8;P¼ .06; SF-36mental
domain 42.7  9 vs 42.4  8; P ¼ .4). Patients aged more
than 80 years had the worst performance on the 6MWT
(262.3 110.4 minutes vs 180.1 64.7 minutes; P¼ .004).
Preoperative median pro-brain natriuretic peptide value
was 1026 pg/mL (IQR, 346-1895 pg/mL), without any dif-
ference according to age. Table 2 shows in detail the preop-
erative echocardiography of the study population. All
patients had an MR grade of 3þ of 4þ at baseline; the
mean left ventricular ejection fraction was 57%  11%.TABLE 2. Preoperative echocardiography
Characteristic Overall (n ¼ 48) Age<80 y (n ¼ 21)
LVEF (%) 57.9  11 55.3  13
LVEF<40% (n,%) 6 (12.5) 4 (19)
LVEDD (mm) 56.9  8 60.4  9
LVESD (mm) 35.3  7 37  8.7
sPAP (mm Hg) 46.4  14 42.1  13
TR 3-4þ (n,%) 9 (19.5) 2 (10)
Central lesion (n,%) 44 (92) 19 (90)
Flail width (mm) 12  2 12.8  3
Flail gap (mm) 4.6  1.4 5.5  1.6
Bold indicates P<.05. ACCESS-EU, ACCESS-EUROPE; DMR, degenerative mitral regur
fraction; LVESD, left ventricle end-systolic diameter; na, not available; sPAP, systolic pul
The Journal of Thoracic and CarProcedural and In-Hospital Outcomes
The device was successfully implanted in 47 of 48
patients (98%); 1 patient was converted to conventional
surgical MV replacement because of clip entanglement in
the subvalvular apparatus in the commissural region, with
the impossibility to retrieve the device.
One clip was implanted in 16 patients (33.3%), 2 clips
were implanted in 29 patients (60.4%), and 3 clips were im-
planted in 2 patients (4.1%). The median procedural time
(defined as the time from start of the transseptal procedure
until the removal of the Steerable Guide Catheter) was 94
minutes (IQR, 69-130 minutes; 6 minutes less compared
with ACCESS-EU DMR).13
Safety outcomes at 30 days are shown in Table 3; 30-day
mortality was 2% (1/48 patients died of septic shock and
multiorgan failure after conversion to open mitral surgery).
There was no incidence of acute myocardial infarction,
stroke, major vascular complication, or cardiac tamponade
at 30 days. Blood transfusion was required in 2 patients
(4%); severe acute renal failure occurred in 1 patientAge 80 y (n ¼ 27) P value ACCESS-EU DMR (n ¼ 117)
59.9  8 .1 na
2 (7.4) .2 11 (9.4)
54.4  6 .01 na
34  6.7 .2 35  9
49.7  14.8 .03 na
7 (27) .1 na
25 (93) .3 na
12.4  2.3 .8 na
4.1  1 .04 na
gitation; LVEDD, left ventricle end-diastolic diameter; LVEF, left ventricular ejection
monary artery pressure; TR, tricuspid regurgitation.
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TABLE 3. Thirty-day safety outcomes
30-d outcome Overall (n ¼ 48) Age<80 y (n ¼ 21) Age 80 y (n ¼ 27) P value ACCESS-EU DMR (n ¼ 117)
Death (n,%) 1 (2) 0 1 (3) .3 7 (6)
Conversion to surgery (n,%) 1 (2) 0 1 (3) .3 2 (1.7)
Stroke (n,%) 0 0 0 — 1 (0.9)
AMI (n,%) 0 0 0 — 1 (0.9)
Renal failure (n,%) 1 (2) 0 1 (3) .3 3 (2.6)
Bleeding complications (n,%) 2 (4) 0 2 (8) .2 4 (3.4)
Cardiac tamponade (n,%) 0 0 0 — 1 (0.9)
ICU stay<24 h (n,%) 36 (75) 18 (81) 18 (70) na
ACCESS-EU, ACCESS-EUROPE; AMI, acute myocardial infarction; DMR, degenerative mitral regurgitation; ICU, intensive care unit; na, not available.
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D(2%). The median stay in the intensive care unit was 22
hours (IQR, 18-24 hours); the stay in the intensive care
unit was less than 1 day in 75% of patients (36/48). Patients
were discharged from the hospital in an average of 4.5 2.4
days (4.3 3 days and 4.7 1.5 days for patients aged<80
years and80 years, respectively; P¼ .7), with a median of
4 days after the MitraClip procedure. A minority of the
patients were transferred to a cardiopulmonary rehabilita-
tion facility (2 patients aged <80 years and 2 patients
aged 80 years; P ¼ .8): 91.5% of hospital survivors
(43/47 patients) were discharged directly home.
Predischarge echocardiography showed anMR reduction
to grade 2þ or less in 43 of 47 patients (91.5%); 29 of 47
patients (61.7%) achieved an MR reduction to grade 1þ
or less. No differences in MR grade reduction were
observed according to age group (Figure 1). No cases of
mitral stenosis were observed: Postprocedural median
MV area was 3 cm2 (IQR, 2.7-3.1 cm2), and predischarge
systolic pulmonary artery pressure was 37.8  10 mm Hg
(P ¼ .03 compared with baseline).
Follow-up
The median follow-up was 16 months (IQR, 2-23
months). Overall actuarial survival was 89%  5.2% andFIGURE 1. MR at baseline and at discharge echocardiography.
2746 The Journal of Thoracic and Cardiovascular Sur70.2%  9% at 1 and 2 years, respectively, for the entire
study population; no differences were observed between
patients aged less than 80 years and patients aged 80 years
or more (82%  9% and 95%  4.4% at 1 year, respec-
tively; P ¼ .9) (Figure 2). Causes of death were classified
as cardiac in 33% of the cases. After discharge, 1 patient
(2%) underwent mitral surgery 2 years after the procedure;
1 patient (2%) repeated the MitraClip procedure 1 month
after the index procedure.
Actuarial freedom from MR 3þ or greater was 80% 
7% at 1 year and 76.6%  7% at 2 years (Figure 3). There
were no statistically significant differences in patients aged
less than 80 years compared with patients aged 80 years or
more (86.5% 8% and 75% 9%, respectively; P¼ .5).
At 1 year, 93% of survivors were in NYHA class I or II
(100% of patients aged<80 years and 88% of patients
aged 80 years; P ¼ .4) (Figure 4).
A significant improvement was documented with all the
quality of life assessments: MLHFQ was 18.1  10, SF-36
physical domain was 44.3  7, and SF-36 mental domain
was 49  8.3 (P<.0001, P ¼ .005, and P ¼ .01, respec-
tively, compared with preoperative values). A significant
improvement in 6MWT performance was observed
(262  91 minutes; mean improvement, 48 minutes;FIGURE 2. Actuarial survival at follow-up in patients aged less than 80
years and patients aged 80 years or more.
gery c December 2014
FIGURE 3. Actuarial freedom from MR 3þ or greater at follow-up.
MR, Mitral regurgitation.
Taramasso et al Acquired Cardiovascular Disease
A
C
DP¼ .005). Significant improvements in perceived quality of
life and performance of 6MWT were observed in both
patients group (Figure 5, A and B).
DISCUSSION
Surgical MV repair is the treatment of choice for patients
with severe DMR.20,21 Therefore, modern MV surgery is
the benchmark for any new technique today, including
MitraClip therapy. However, MR is a frequent condition
in elderly persons (especially degenerative cause).9,22
Advanced age is one of the main risk factors of mortality
and morbidity after cardiac surgery (78% of the major
complications after cardiac surgery and deaths occurred in
elderly patients).23 Although favorable outcomes are re-
ported even in elderly patients after isolated mitral repair,3
operative mortality and morbidity are high in elderly pa-
tients in the presence of co-pathologies and associated
surgical procedures.22
Badhwar and colleagues24 recently reported the out-
comes after MV repair in 14,604 patients aged more thanFIGURE 4. NYHA functional class at baseline and 1 year.
The Journal of Thoracic and Car65 years. In patients aged more than 80 years with advanced
heart failure symptoms (NYHAclass III-IV), operativemor-
tality was 5.3% and 5-year survival was 68%. The 5-year
rates of recurrence of heart failure, major bleeding, and
stroke were 28.8%, 12.3%, and 11.7%, respectively.
Seeburger and colleagues25 reported the single-center
experience with 2053 elderly (aged 70 years) patients
who underwent MV surgical procedures with or without
associated procedures. Seventy-seven patients (3.1%)
died within 30 days after the operation. Cerebrovascular
accidents occurred in 4.2% of patients, and the incidence
of acute renal failure was 16.7%. Concomitant coronary
artery bypass grafting was a significant risk factor for
increased early mortality. Five-year survival for patients
aged more than 80 years was 47.9%, and associated comor-
bidities were associated with an increased risk of late death.
Chikwe and colleagues26 reported the results of a consec-
utive series of 322 octogenarians operated over a period of
10 years. Approximately half of the patients underwent MV
surgery combined with coronary artery bypass grafting. The
surgical risk was apparently acceptable only in patients
treated with an isolated elective repair, with a mortality of
approximately 5% at 30 days. However, mortality at 3
months was approximately 13%, indicating that octogenar-
ians are not likely to recover easily from the trauma of open
surgery.
Currently, up to 50% of the patients with severe MR are
not referred for surgery because of high predicted surgical
risk or advanced age.8 According to the European Society
of Cardiology 2012 Guidelines,7 percutaneous edge-to-
edge procedure may be considered in patients with symp-
tomatic severe DMR who fulfill the echocardiographic
criteria of eligibility, are judged inoperable or at high surgi-
cal risk by a heart team, and have a life expectancy greater
than 1 year (class IIb, level of evidence C).
Data from the Endovascular Valve Edge-to-Edge Repair
of Mitral Regurgitation Study (EVEREST) trials and from
registries in Europe and the United States showed that the
MitraClip procedure has a procedural success rate (postpro-
cedural MR 2þ) of approximately 75% and is relatively
safe and generally well tolerated, even by patients in poor
clinical condition.10-18 Patients currently treated in the
real world with MitraClip therapy for DMR are different
from those enrolled in the EVEREST II randomized trial,
which included surgical low-risk candidates. The High
Risk Registry Study, an arm of the EVEREST II trial,
enrolled symptomatic patients with moderate to severe or
severe MR for whom surgical risk for perioperative mortal-
ity rate was estimated to be greater than 12% with STS
score. In this series, 88.5% of the patients had 5 or more
associated co-pathologies and 83% of the patients were
aged more than 75 years.17 A degenerative cause was pre-
sent in 62 patients. At 30 days, 4 of 62 patients (6.5%)
with DMR who were treated with MitraClip died.diovascular Surgery c Volume 148, Number 6 2747
FIGURE 5. A, Results of MLHFQ in patients aged less than 80 years and patients aged 80 years or more. B, Results of 6MWT in patients aged less than 80
years and patients aged 80 years or more. MLHFQ, Minnesota Living with Heart Failure Questionnaire; 6MWT, 6-minute walk test.
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I study showed satisfactory clinical outcomes in selected
high-risk patients13: A total of 117 patients (mean age,
75.6  12 years; mean logistic euroSCORE, 15.5% 
13.3%) with DMR underwent the MitraClip procedure.
However, a 30-day mortality of 6.0% was reported. In a
subgroup of patients with particularly high risk (mean logis-
tic euroSCORE 33%  11%), observed mortality was
9.1%. Likewise, Lim and colleagues18 reported a 6.3%
30-day mortality in 141 high-risk patients with DMR
(mean age, 82 years).
The major finding of the present study concerns the
high level of safety of MitraClip therapy in high-risk
and elderly patients with DMR if appropriate patient2748 The Journal of Thoracic and Cardiovascular Surselection is performed. In our experience, 30-day mortality
was remarkably low (2% overall; 3% in patients aged>80
years). Although patients treated in San Raffaele University
Hospital experience were older compared with those in the
ACCESS-EU DMR, they had a similar baseline risk profile
(logistic euroSCORE, 15.7  12.2). The relatively higher
30-day mortality reported in the registries may reflect the
fact that they are real-world registries, in which many pro-
cedures, at least at the beginning of the enrollment, were
performed in very sick patients as compassionate and prob-
ably futile treatment. The low mortality and extremely low
morbidity reported in our experience show the importance
of careful patient selection to identify those who could
benefit from the procedure and to reduce procedural risk.gery c December 2014
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DIt is important to point out that patient selection is funda-
mental to obtain successful procedural results. In our expe-
rience, we observed a procedural success of 98%, which is
satisfactory, especially in degenerative cause, and favorably
compares with other large real-world MitraClip series of
patients with DMR (94% in ACCESS-EU DMR,13
80% reported by Rudolph and colleagues14 in patients
with DMR).
At follow-up, we observed an actuarial survival of 89%
 5.2% and 70.2%  9% at 1 and 2 years, respectively,
without differences between patients aged less than 80 years
and patients aged 80 years or more, which favorably com-
pares with other MitraClip series (1-year mortality ranging
from 6% to 24%) and with the previously mentioned
surgical reports.15-18
In regard to echocardiographic outcome, our experience
showed an acute reduction of MR to grade 2þ or less in
91.5%, and in 61.7% an MR reduction to grade 1 or
less was achieved. These results are consistent with those
reported in the ACCESS DMR registry (reduction of MR
to grade 2þ in 88.7%) and favorably compared with the
EVEREST II trial (77%).10,13 Freedom from MR 3þ or
greater was 80%  7% and 76.6%  7% at 1 and 2
years, respectively. If compared with reparative mitral
surgery, these results are inferior, confirming that
surgery is so far the gold standard therapy for DMR.
However, it should be considered that the patients
included in the present study, like the majority of the
patients currently treated with MitraClip, are high-risk
surgical candidates or inoperable patients. Although esti-
mated surgical risk was high, meaningful clinical im-
provements were documented. In fact, except for
intraoperative and early postoperative risks, it would
seem equally or even more important, especially in
elderly patients, integrated evaluation of the quality of
life and functional status, to judge whether a certain pro-
cedure could lead to the expected functional improve-
ment. In a retrospective study including 225 patients
aged more than 70 years who underwent mitral surgery
for severe DMR, Maisano and colleagues27 demonstrated
that quality of life after surgery is suboptimal in more
than half of the patients, even if the patient survives after
the operation.
Important clinical benefits were documented at 1 year
even in patients aged more than 80 years, in terms of
NYHA class, quality of life, and functional status tested
by walk test improvements. In our experience, MLHFQ
scores, SF-36 scores, and 6MWT performance improved
significantly at 12 months compared with baseline
(P ¼ .03 and P<.0001, respectively). Significant improve-
ments were observed in patients aged more than 80 years.
This is consistent with the ACCESS-EU DMR results at
1 year and with other reports in different clinical
settings.10,12,17,28The Journal of Thoracic and CarStudy Limitations
This study was an observational, retrospective, single-
center study; therefore, the sample size is too small to
make strong conclusions. Moreover, the results include an
initial learning curve.CONCLUSIONS
The results of this single-center experience confirm that
MitraClip therapy is a valuable alternative to surgery in
high-risk and elderly patients with DMR. Clinical benefits
are evident at 1 year and also obtained in octogenarians.
Although patients treated in current practice are high risk,
the procedure remains safe and effective in selected
patients. Durability of MR reduction and clinical benefit
warrant further monitoring of patients after MitraClip
implantation during long-term follow-up.References
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ment of high-risk patients. J Thorac Cardiovasc Surg. 2012;143:78-84.MMENTARYPercutaneous edge-to-edge repair for degenerative mitral regurgitation:
A journey to the edge of the bell-shaped curvePatrick M. McCarthy, MDThe report in this issue of the Journal by Taramasso and
colleagues1 is a welcome addition, as most reports ofMitra-
Clip (Abbott Vascular, Santa Clara, Calif) outcomes have
been in the cardiology literature. Taramasso and col-
leagues1 report excellent outcomes in a high-risk surgical
population (78.5  10.8 years; 71% New York HeartAssociation functional class III or IV; mean Society of
Thoracic Surgeons [STS] score 12%  10%) with severe
degenerative mitral regurgitation (DMR). Their results
mirror the US MitraClip experience presented to the Food
and Drug Administration panel with a low procedural risk
(2% in-hospital mortality), low morbidity, no clip emboli-
zation, a very high procedural ‘‘success’’ rate (98%), and
short stay relative to conventional surgery.2 DMR
frequently is seen with an anatomically difficult lesion to
treat with the MitraClip; however, there was a reasonable
reduction in mitral regurgitation to grade II or less in
91.5% of patients. The 1-year survival (89%  5.2%),
New York Heart Association functional class (93% I or
II), and 6-minute walk (mean improvement of 48 meters)
were favorable. Initial trials in the United States included
low- and medium-risk patients, the type of patients in the
middle of the bell-shaped curve of patients treated with sur-
gery, and reflected a strategy (and hubris) to compete
directly with conventional heart surgery. These trials, prin-
cipally the Endovascular Valve Edge-to-Edge Repair High
Risk Study (EVEREST) and the continued access protocol,
took a long time to execute as the tactics evolved and the
target patient population shifted to the sickest patients ongery c December 2014
